Search Results - "Bartalotta, Amy"

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs by Gadelha, Mônica, Bex, Marie, Colao, Annamaria, Pedroza García, Elier Mitsael, Poiana, Catalina, Jimenez-Sanchez, Marisela, Yener, Serkan, Mukherjee, Rishav, Bartalotta, Amy, Maamari, Ricardo, Raverot, Gérald

“…Acromegaly is a rare, serious endocrine disorder characterized by excess growth hormone (GH) secretion by a pituitary adenoma and overproduction of…”
Get full text

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial by Strosberg, Jonathan R, Caplin, Martyn E, Kunz, Pamela L, Ruszniewski, Philippe B, Bodei, Lisa, Hendifar, Andrew, Mittra, Erik, Wolin, Edward M, Yao, James C, Pavel, Marianne E, Grande, Enrique, Van Cutsem, Eric, Seregni, Ettore, Duarte, Hugo, Gericke, Germo, Bartalotta, Amy, Mariani, Maurizio F, Demange, Arnaud, Mutevelic, Sakir, Krenning, Eric P

“…The primary analysis of the phase 3 NETTER-1 trial showed significant improvement in progression-free survival with 177Lu-Dotatate plus long-acting octreotide…”
Get full text

177 Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial by Strosberg, Jonathan R, Caplin, Martyn E, Kunz, Pamela L, Ruszniewski, Philippe B, Bodei, Lisa, Hendifar, Andrew, Mittra, Erik, Wolin, Edward M, Yao, James C, Pavel, Marianne E, Grande, Enrique, Van Cutsem, Eric, Seregni, Ettore, Duarte, Hugo, Gericke, Germo, Bartalotta, Amy, Mariani, Maurizio F, Demange, Arnaud, Mutevelic, Sakir, Krenning, Eric P

“…The primary analysis of the phase 3 NETTER-1 trial showed significant improvement in progression-free survival with Lu-Dotatate plus long-acting octreotide…”
Get full text

Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors by Strosberg, Jonathan R., Caplin, Martyn E, Kunz, Pamela L., Ruszniewski, Philippe B, Bodei, Lisa, Hendifar, Andrew Eugene, Mittra, Erik, Wolin, Edward M., Yao, James C., Pavel, Marianne E, Grande, Enrique, Van Cutsem, Eric, Seregni, Ettore, Duarte, Hugo, Gericke, Germo, Bartalotta, Amy, Demange, Arnaud, Mutevelic, Sakir, Krenning, Eric

“…Abstract only 4112 Background: As demonstrated in the primary analysis of the phase 3 NETTER-1 trial, 177 Lu-DOTATATE significantly prolonged progression-free…”
Get full text

SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‑Generation Somatostatin Analogues (SSAs): Results from Phase 3b, Open-Label Study by Gadelha, Mônica, Colao, Annamaria, Bex, Marie, Campigotto, Federico, Bartalotta, Amy, Maamari, Ricardo, Raverot, Gérald

“…Background: In a 24-week, Phase 3 study (PAOLA), long-acting pasireotide demonstrated superior efficacy (GH <2.5 µg/L and IGF-1 <ULN) over continued treatment…”
Get full text